Phreesia Announces Fiscal First Quarter 2022 Results

Raleigh, North Carolina, April 30, 2021 - Phreesia, Inc. (NYSE: PHR) ("Phreesia") announced financial results today for the fiscal first quarter ended April 30, 2021.

"We carried the momentum of the strong finish to our fiscal year 2021 into the first guarter of fiscal 2022. As we look ahead, we're excited to continue providing health systems, hospitals and ambulatory providers with tools that will help them optimize their performance and improve the patient experience," said Phreesia CEO Chaim Indig.

Fiscal First Quarter 2022 Highlights

- Revenue was \$48.3 million in the quarter as compared to \$33.4 million in the same period in the prior year, an increase of 45%.
- Average number of provider clients was 1,902 in the guarter as compared to 1,632 in the same period in the prior year, an increase of 17%.
- Average revenue per provider client was \$20,222 in the guarter compared to \$16,735 in the same period in the prior year, an increase of 21%.
- Adjusted EBITDA was positive \$0.1 million in the quarter compared to positive \$1.5 million in the same period in the prior year.
- Cash and cash equivalents as of April 30, 2021 was \$450.7 million, an increase of \$231.9 million compared to January 31, 2021, driven primarily by our follow-on offering of common stock, which generated net proceeds of \$245.8 million.

Outlook for Fiscal 2022

We are increasing our revenue outlook for fiscal 2022 to a range of \$191 million to \$194 million from the previous range of \$178 million to \$186 million. We continue to expect our overall cash outflow to increase in fiscal 2022 compared to fiscal 2021 as we continue to ramp up hiring and infrastructure across the organization to support our anticipated growth. **Conference Call Information**

The Company will hold a conference call on Friday, June 4, 2021, at 8:30 a.m. Eastern Time to review the Company's first fiscal quarter financial results. To participate in the Company's live conference call and webcast, please dial (866) 211-4557 (or (647) 689-6750 for international participants) using conference code number 3966898 or visit the "Events & Presentations" section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Recent Events

COVID-19

The impact of the COVID-19 (a novel strain of coronavirus) pandemic has been widespread and rapidly evolving. Over the last six months, several vaccines for COVID-19 received FDA approval and are currently being administered across the country. To date, more than a third of Americans are fully vaccinated against the virus. Despite the promising vaccination rates and many states' reopening plans, we believe COVID-19 may continue to impact the normal operations of our clients, which are primarily healthcare providers. As more individuals are vaccinated, we expect these impacts to be diminished.

Phreesia, Inc. Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data)

		April 30, 2021	January 31, 2021	
		(unaudited)		
Assets				
Current:				
Cash and cash equivalents	\$	450,680	\$	218,781
Settlement assets		16,788		15,488
Accounts receivable, net of allowance for doubtful accounts of \$666 and \$699 as of April 30, 2021 and January 31, 2021, respectively		29,964		29,052
Deferred contract acquisition costs		1,895		1,693
Prepaid expenses and other current assets		7,906		7,254
otal current assets		507,233		272,268
Property and equipment, net of accumulated depreciation and amortization of \$43,442 and \$40,148 as of April 30, 2021 and January 31, 2021, respectivel	у	25,068		26,660
Capitalized internal-use software, net of accumulated amortization of \$26,998 and \$25,476 as of April 30, 2021 and January 31, 2021, respectively		11,225		10,476
Operating lease right-of-use assets		2,497		2,654
Deferred contract acquisition costs		2,438		1,248
Intangible assets, net of accumulated amortization of \$653 and \$525 as of April 30, 2021 and January 31, 2021, respectively		2,597		2,72
Deferred tax asset		533		65
Goodwill		8,211		8,30
Other assets		1,401		1,670
otal assets	\$	561,203	\$	326,666
iabilities and Stockholders' Equity				
Current:				
Settlement obligations	\$	16,788	\$	15,488
Current portion of debt and finance lease liabilities		4,103		4,864
Current portion of operating lease liabilities		1,153		1,087
Accounts payable		313		4,389
Accrued expenses		15,116		18,324
Deferred revenue		13,223		10,83
otal current liabilities		50,696	_	54,990
Long-term debt and finance lease liabilities		5,532		6,47
Operating lease liabilities, non-current		1,701		1,899
otal liabilities		57,929		63,360
Commitments and contingencies	_			
Stockholders' Equity:				
Common stock, \$0.01 par value - 500,000,000 shares authorized as of April 30, 2021 and January 31, 2021, respectively; 50,270,229 and 44,880,883 shares issued as of April 30, 2021 and January 31, 2021, respectively		503		449
Additional paid-in capital		831,632		579,599
Accumulated deficit		(322,751)		(311,777
Treasury stock, at cost, 119,138 and 99,520 shares at April 30, 2021 and January 31, 2021, respectively		(6,110)		(4,965
otal Stockholders' Equity		503,274		263,300
otal Liabilities and Stockholders' Equity	-		\$	326,666

Phreesia, Inc. Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share data)

	Three months ended April 30,			
	2021		2020	
Revenue:				
Subscription and related services	\$ 21,819	\$	15,599	
Payment processing fees	16,644		11,707	
Life sciences	 9,828		6,090	
Total revenues	48,291		33,396	
Expenses:				
Cost of revenue (excluding depreciation and amortization)	8,534		4,734	
Payment processing expense	9,725		6,848	
Sales and marketing	15,012		9,434	
Research and development	8,054		5,005	
General and administrative	12,671		8,720	
Depreciation	3,297		2,268	
Amortization	 1,651		1,353	
Total expenses	58,944		38,362	
Operating loss	(10,653)		(4,966)	
Other income (expense), net	66		(715)	
Interest (expense) income, net	 (238)		(320)	
Total other expense, net	(172)		(1,035)	
Loss before provision for income taxes	(10,825)		(6,001)	
Provision for income taxes	(149)		(111)	
Net loss	\$ (10,974)	\$	(6,112)	
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.24)	\$	(0.16)	
Weighted-average common shares outstanding, basic and diluted	45,416,431		37,308,084	

Phreesia, Inc. Consolidated Statements of Cash Flows (unaudited) (in thousands)

Net loss \$ (10.974) \$ (6, 11 Adjustments for concile net loss tone tash (used in) provided by operating activities: - - - - - - 2.8 3.63 - - - 2.8 3.63 - - 2.8 3.63 - - 2.8 3.63 - - 2.8 3.63 - - 2.8 3.63 - - 2.8 - 3.63 - - 2.8 - 3.63 - 1.10 - - 2.8 - 3.63 - 1.10 - 1.10 - 1.10 - - - 1.10 - 1.10 - 1.10 - 1.10 - 1.10 1.10 - 1.10		Three Months Ended April 30,		
Net loss \$ (10.974) \$ (6, 11 Adjustments for concile net loss net cash (used in) provided by operating activities: -		 2021	2020	
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Depreciation and amortization 4.948 3.63 Stock-based compensation expense Stock-based compensation expense Cost of Phreesia hardware purchased by customers Cost of Phreesia hardware purchased by customers Cost of Phreesia hardware purchased by customers Stock-based compensation cost anontization Deferred contract acquisition cost amortization Non-cash operating lease expense Changes in operating assets and liabilities: Changes in operating assets and other assets Deferred contract acquisition costs Accounts payable Accounts payable Accounts payable Lease liability Lease liability Capitalized inhemal-use software Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter' discounts and commissions Proceeds from issuance of ommon stock in equity offerings, net of underwriter's discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter's discounts and commissions Proceeds from issuance of common stock in equity offerings, net of underwriter's discounts and cost equitate	Operating activities:			
Depreciation and amoritization 4,448 3,66 Stock-based compensation expense 5,774 2,81 Amortization of debt discount 72 11 Cost of Phreesia hardware purchased by customers 135 11 Deferred contract acquisition cost amortization 5,75 6,55 Non-cash operating lease expense 2,56 33 Deferred contract acquisition cost amortization 105 105 Charges in operating assets and liabilities: (1912) (2,2,2 Charges in operating assets and liabilities: (1967) (77 Accounts receivable (1967) (77 Accounts payable (1,967) (1,66) Accounts payable (1,967) 1,96 Accounts payable (1,967) 1,96 Investing activities: (5,773) 1,96 Captalized internal-use software (2,916) (1,166 Proceeds from issuance of common stock in equity offends, net of underwriters' discounts and commissions 245,813 - Proceeds from issuance of offening oanstock compensation awards (1,195) -	Net loss	\$ (10,974)	\$ (6,112)	
Stock-based compensation expense 5,774 2,81 Amortization of debt discount 72 12 Cost of Phreesia hardware purchased by customers 135 11 Deferred contract acquisition cost amortization 575 65 Non-cash operating leases expense 256 33 Deferred tax asset 125 45 Changes in operating leases expense (809) 1,67 Changes in operating assets and liabilities: (809) 1,67 Accounts receivable (812) (2,24 Prepaid expenses and other assets (1,067) (7 Accound expenses and other assets (1,068) (689) Deferred contract acquisition costs (1,068) (689) Deferred contract acquisition costs (3,678) 1,88 Lease liability (3,678) 1,88 Lease liability (3,678) 1,90 Deferred contract acquisition costs (2,916) (1,1,16 Capitalization internate of common stock in equity offerings, net of underwriter's discounts and commissions 24,513 - Proceeds from issoua	Adjustments to reconcile net loss to net cash (used in) provided by operating activities:			
Amortization of debt discount 72 11 Cost of Phreesia hardware purchased by customers 135 11 Deferred contract acquisition cost amortization 575 56 Non-cash operating lease expense 256 33 Deferred contract acquisition cost amortization (809) 1.6 Changes in operating assets and liabilities: (809) 1.6 Accounts receivable (809) 1.6 Deferred contract acquisition costs (1,967) (77) Accounds payable (1,068) (982) Accound sequences and other liabilities: (3,678) 1.83 Lease liability (3,3678) 1.83 Lease liability (3,3678) 1.83 Lease liability (3,3678) 1.83 Lease liability (3,478) 1.22 Next (use (a in) provided by operating activities (5,473) 1.99 Investing activities: (6,4893) 1.91 Proceeds from issuance of common stock upon exercise of stock options 1.356 1.72 Proceeds from issuance of common stock upon exercise of stock options<	Depreciation and amortization	4,948	3,621	
Cost of Phreesia hardware purchased by customers 135 11 Deferred contract acquisition cost amontization 575 55 Non-cash operating lease expense 256 33 Deferred tax asset 125 45 Changes in operating lease expense (809) 1.6 Accounts receivable (809) 1.6 Deferred contract acquisition costs (1967) (77 Accounts receivable (1088) (98 Deferred contract acquisition costs (3078) 1.8 Accounts payable (1088) (98 Accounts quick and ther liabilities (3378) 1.2 Lease liability (335) (65 Deferred orevenue 2.335 1.2 Net cash (used in hyroxited by operating activities (2,916) (1,11 Purchase of property and equipment (3,983) (1,1967) Purchase of property and equipment (3,983) (1,997) Not cash used in investing activities (6,899) (3,07) Finance lease payments (1,196) (1,196) (1,196)	Stock-based compensation expense	5,774	2,872	
Deferred contract acquisition cost amorfization 575 55 Non-cash operating lease expense 256 33 Deferred tax asset 125 94 Changes in operating assets and liabilities: 912 (2,22 Prepaid expenses and other assets (809) 1,65 Deferred tax asset (1,967) (77 Accounts receivable (1,967) (77 Accounts receivable (3,678) 1,85 Deferred acquisition costs (1,068) (09 Accounts receivable (3,678) 1,85 Lease liability (335) (55 Deferred revenue 2,385 1,22 Vet task used in provided by operating activities (2,916) (1,116 Capitalized internal-use software (2,916) (1,116 Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,77 Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 <td< td=""><td>Amortization of debt discount</td><td>72</td><td>126</td></td<>	Amortization of debt discount	72	126	
Non-cash operating lease expense 256 36 Deferred tax asset 125 42 Changes in operating assets and liabilities: (912) (2.24 Prepaid expenses and other assets (809) 1.65 Deferred contract acquisition costs (1,967) (77 Accounts payable (1,068) (982) Caperating assets and other liabilities: (3,678) 1.85 Lease liability (335) (56 Deferred revenue (2,385) 1.22 Prepaid expenses and other liabilities: (5,473) 1.99 Deferred revenue (2,385) (56 Non-cast oppropring activities: (5,473) 1.99 Investing activities: (5,473) 1.99 Purchase of property and equipment (2,916) (1,167 Proceeds from issuance of common stock in equily offerings, net of underwriters' discounts and commissions 245,813 - Proceeds from issuance of common stock compensation awards (1,145) - - Proceeds from issuance of common stock compensation awards (1,145) - -	Cost of Phreesia hardware purchased by customers	135	172	
Deferred tax asset 125 125 125 Changes in operating assets and liabilities:	Deferred contract acquisition cost amortization	575	525	
Changes in operating assets and liabilities: (912) (2.22 Accounts receivable (909) 1.6 Deferred contract acquisition costs (1,967) (77 Accounts payable (1,068) (989) Accrued expenses and other liabilities (3,678) 1.83 Lease liability (3,35) (55 Deferred revenue 2.385 1.22 Nest cash (used in) provided by operating activities (5,473) 1.90 Capitalized internal-use software (2,916) (1,146 Purchase of property and equipment (3,983) (1,99) Vet cash used in investing activities (6,899) (3,00) Financing activities (1,145) - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,72 Proceeds from issuance of common stock upon exercise of stock options 1,356 1,72 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,72 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - <t< td=""><td>Non-cash operating lease expense</td><td>256</td><td>389</td></t<>	Non-cash operating lease expense	256	389	
Accounts receivable (912) (2,24 Prepaid expenses and other assets (809) 1.6' Deferred contract acquisition costs (1,967) (7') Accounts payable (1,068) (98) Accounts payable (1,068) (98) Accounts payable (3,678) 1.8' Lease liability (335) (55) Deferred revenue 2,385 1.2' Ivesting activities: (5,473) 1.9' Capitalized internal-use software (2,916) (1,16' Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' Proceeds from issuance of common stock upon exercise of stock options 1,356 1,7' <td>Deferred tax asset</td> <td>125</td> <td>56</td>	Deferred tax asset	125	56	
Prepaid expenses and other assets(809)1.6'Deferred contract acquisition costs(1,967)(7'Accounts payable(1,068)(96Accrued expenses and other liabilities(3,678)1.8'Lease liability(335)(5CDeferred revenue2,3851.2'Net cash (used in) provided by operating activities(5,473)1.9'Investing activities:(5,473)1.9'Capitalized internal-use software(2,916)(1,16)Purchase of property and equipment(3,983)(1,9')Net cash used in investing activities(6,899)(3,0')Financing activities:(6,899)(3,0')Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813Proceeds from issuance of common stock compensation awards(1,145)Proceeds form issuance of common stock compensation awards(1,145)Prinarce lease payments(1,050)(52Prinarce lease payments(673)Vet increase (decrease)(673)Vet increase (decrease)(23,899)(1Vet increase (decrease)(1,21,115)Vet increase (decrease)(1,21,115)Vet increase (decrease)(1,21,115)Vet increase (decrease)(1,23,115)Vet increase (decrease)(1,23,115)Vet increase (decrease)(1,23,115)Vet increase (decrease)(1,21,115)Vet increase (dec	Changes in operating assets and liabilities:			
Deferred contract acquisition costs(1,967)(71Accounts payable(1,068)(99Accured expenses and other liabilities(3,678)1,88Lease liability(335)(50Deferred revenue2,3851,22Net cash (used in) provided by operating activities(5,473)1,90Investing activities:(2,916)(1,14Purchase of property and equipment(3,983)(1,99Net cash used in investing activities(6,899)(3,07)Financing activities:(6,899)(3,07)Proceeds from issuance of common stock upon exercise of stock options1,3561,72Proceeds from issuance of common stock compensation awards(1,145)-Proceeds from issuance of common stock compensation awards(1,145)-Proceeds from issuance of common stock compensation awards(1,050)(52Financing activities:(30)Proceeds from issuance of common stock compensation awards(1,145)-Proceeds from issuance of common stock compensation awards(1,145)-Proceeds from issuance of common stock upon exercise of stock options(30)-Finance lease payments(1,050)(52Finance lease payments(1,050)(52Loan facility fee payment-(10Loan facility fee payments-(10Ket cash provided by financing artivities243,189(0Cash and cash equivalents - beginning of period218,78190,33	Accounts receivable	(912)	(2,245)	
Accounts payable(1,060)(99Accrued expenses and other liabilities(3,678)1,83Lease liability(335)(65Deferred revenue2,3851,22Net cash (used in) provided by operating activities(5,473)1,90Capitalized internal-use software(2,916)(1,14Purchase of property and equipment(3,983)(1,91Net cash used in investing activities(6,899)(3,07Financing activities(6,899)(3,07Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813-Proceeds from issuance of common stock upon exercise of stock options(1,145)-Proceeds from issuance of common stock compensation awards(1,145)-Proceeds from issuance of common stock upon exercise of stock options(1,050)(55Principal payments of offering costs(30)Finance lease payments(1,050)(55Vet cash provided by financing arrangements(673)(1050)Loan facility fee payment-(10,050)(55(10,050)-Net cash provided by financing activities\$244,271\$1,111,11Net cash provided by financing activities\$244,271\$1,11(10,050)1,111,111,11 <td< td=""><td>Prepaid expenses and other assets</td><td>(809)</td><td>1,614</td></td<>	Prepaid expenses and other assets	(809)	1,614	
Accrued expenses and other liabilities(3,678)1,85Lease liability(335)(50Deferred revenue2,3851,22Net cash (used in) provided by operating activities(5,473)1,90Investing activities(2,916)(1,16Purchase of property and equipment(3,983)(1,91Net cash used in investing activities(6,899)(3,07)Financing activities(6,899)(3,07)Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813Proceeds from issuance of common stock upon exercise of stock options1,3561,77Treasury stock to satisfy tax withholdings on stock compensation awards(1,145)-Payments of offering costs(30)Finance lease payments(1,050)(52(57)-Loan facility fee payment-(1050)(52Net cash provided by financing activities\$244,271\$1,17Ket cash provided by financing activities-(10,50)(52Principal payments on financing arrangements-(10,50)(52Loan facility fee payment(10,50)-Net cash provided by financing activities\$244,271\$1,17Stata payments(10,50)Loan facility fee payment(10,50)-Net cash provided by financing activities\$244,271\$1,17Stata payments <td>Deferred contract acquisition costs</td> <td>(1,967)</td> <td>(714)</td>	Deferred contract acquisition costs	(1,967)	(714)	
Lease liability(335)(50Deferred revenue2,3851,22Net cash (used in) provided by operating activities(5,473)1,90Investing activities:(2,916)(1,16Purchase of property and equipment(3,983)(1,99)Net cash used in investing activities(6,899)(3,07)Financing activities:(6,899)(3,07)Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813Proceeds from issuance of common stock upon exercise of stock options1,3561,73Treasury stock to satisfy tax withholdings on stock compensation awards(1,145)-Payments of offering costs(30)-Financing activities(1,050)(652Principal payments on financing arrangements(673)-Loan facility fee payment-(1050)Net cash provided by financing activities231,899(0Capital activities231,899(0Capit			(998)	
Deferred revenue2,3851,22Net cash (used in) provided by operating activities(5,473)1,90investing activities:(2,916)(1,16Capitalized internal-use software(2,916)(1,16Purchase of property and equipment(3,983)(1,99)Net cash used in investing activities(6,899)(3,07)Financing activities:(6,899)(3,07)Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813Proceeds from issuance of common stock upon exercise of stock options1,3561,77Proceeds from issuance of common stock compensation awards(1,145)-Payments of offering costs(30)Finance lease payments(1,050)(52Principal payments on financing arrangements(673)-Loan facility fee payment-(10Net cash provided by financing activities§244,2711,11Net increase (decrease) in cash and cash equivalents231,899(0Cash and cash equivalents - beginning of period218,78190,37			1,871	
Net cash (used in) provided by operating activities (5,473) 1,99 Investing activities: (2,916) (1,16 Purchase of property and equipment (3,983) (1,99) Net cash used in investing activities (6,899) (3,07) Financing activities: (6,899) (3,07) Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,73 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (1,050) (673) - Finance lease payments (673) - (10,050) (52 Principal payments on financing arrangements (673) - (10,050) (52 Loan facility fee payment - - (10,050) (52 Net cash provided by financing activities \$ 244,271 \$ 1,11 Net cash provided by financing activities \$ 231,899 (67) State activities 231,899 (67) (67) (67) Ne		()	(502)	
Investing activities: (2,916) (1,16) Capitalized internal-use software (3,983) (1,91) Purchase of property and equipment (3,983) (1,91) Net cash used in investing activities (6,899) (3,07) Financing activities: (1,145) (1,145) Proceeds from issuance of common stock upon exercise of stock options (1,145) (1,145) Proceeds from issuance of common stock compensation awards (1,145) (1,145) Payments of offering costs (30) (673) Finance lease payments (673) (673) Loan facility fee payment (1,050) (52) Loan facility fee payment (1,050) (100) Net cash provided by financing activities (1,050) (100) Net cash provided by financing activities (231,899) (100) Cash and cash equivalents – beginning of period (218,781) (90,3)	Deferred revenue	2,385	1,228	
Capitalized internal-use software(2,916)(1,16)Purchase of property and equipment(3,983)(1,943)Net cash used in investing activities(6,899)(3,073)Financing activities:(6,899)(3,073)Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions245,813-Proceeds from issuance of common stock upon exercise of stock options(1,145)-Treasury stock to satisfy tax withholdings on stock compensation awards(1,145)-Payments of offering costs(1,050)(52Finance lease payments(1,050)(52Principal payments on financing arrangements(673)-Loan facility fee payment-(10Net cash provided by financing activities\$ 244,271 \$ 1,11Net increase (decrease) in cash and cash equivalents231,899(6Cash and cash equivalents - beginning of period218,78190,31	Net cash (used in) provided by operating activities	 (5,473)	1,903	
Purchase of property and equipment (3,983) (1,91) Net cash used in investing activities (6,899) (3,07) Financing activities: (6,899) (3,07) Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,77 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (1,050) (52 Finance lease payments (1,050) (52 Principal payments on financing arrangements (1,050) (52 Loan facility fee payment - (100) Net cash provided by financing activities \$ 244,271 \$ 1,11 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,37	Investing activities:			
Net cash used in investing activities (6,899) (3,07 Financing activities: (6,899) (3,07 Proceeds from issuance of common stock upon exercise of stock options 245,813 - Proceeds from issuance of common stock upon exercise of stock options 1,356 1,77 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (30) - Finance lease payments (1,050) (52 Principal payments on financing arrangements (1,050) (52 Loan facility fee payment - (10 Net cash provided by financing activities \$ 244,271 \$ 1,11 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,37	Capitalized internal-use software	(2,916)	(1,160)	
Financing activities: (1.1.1.2) Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 Proceeds from issuance of common stock upon exercise of stock options 1,356 1,73 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (30) - Finance lease payments (1,050) (652 Principal payments on financing arrangements (1,050) (52 Loan facility fee payment - (1145) Net cash provided by financing activities \$ 244,271 \$ 1,11 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,37	Purchase of property and equipment	 (3,983)	(1,917)	
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 Proceeds from issuance of common stock upon exercise of stock options 1,356 1,73 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (30) - Finance lease payments (1,050) (672) Principal payments on financing arrangements (10,050) (102) Loan facility fee payment - (110) Net cash provided by financing activities \$ 244,271 \$ 1,17 Net increase (decrease) in cash and cash equivalents 231,899 (672) (110) (110) Cash and cash equivalents – beginning of period 218,781 90,37 90,37	Net cash used in investing activities	(6,899)	(3,077)	
Proceeds from issuance of common stock upon exercise of stock options 1,356 1,73 Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) - Payments of offering costs (30) - Finance lease payments (1,050) (673) Principal payments on financing arrangements (673) - Loan facility fee payment - (100) Net cash provided by financing activities \$ 244,271 \$ 1,17 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,37	Financing activities:			
Treasury stock to satisfy tax withholdings on stock compensation awards (1,145) Payments of offering costs (30) Finance lease payments (1,050) Principal payments on financing arrangements (673) Loan facility fee payment — Net cash provided by financing activities \$ 244,271 \$ 1,17 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,37	Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions	245,813		
Payments of offering costs (30) - Finance lease payments (1,050) (52 Principal payments on financing arrangements (673) - Loan facility fee payment - (10 Net cash provided by financing activities \$ 244,271 \$ 1,11 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,31	Proceeds from issuance of common stock upon exercise of stock options	1,356	1,736	
Finance lease payments (1,050) (52 Principal payments on financing arrangements (673) - Loan facility fee payment - (100) Net cash provided by financing activities \$ 244,271 \$ 1,17 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents - beginning of period 218,781 90,37	Treasury stock to satisfy tax withholdings on stock compensation awards	(1,145)	_	
Principal payments on financing arrangements (673) - Loan facility fee payment - (10) Net cash provided by financing activities \$ 244,271 \$ 1,17 Net increase (decrease) in cash and cash equivalents 231,899 (6) Cash and cash equivalents – beginning of period 218,781 90,37	Payments of offering costs	(30)	_	
Loan facility fee payment	Finance lease payments	(1,050)	(525)	
Net cash provided by financing activities \$ 244,271 \$ 1,11 Net increase (decrease) in cash and cash equivalents 231,899 (6 Cash and cash equivalents – beginning of period 218,781 90,31	Principal payments on financing arrangements	(673)	_	
Net increase (decrease) in cash and cash equivalents231,899(6Cash and cash equivalents - beginning of period218,78190,33	Loan facility fee payment	_	(100)	
Cash and cash equivalents – beginning of period 218,781 90,32	Net cash provided by financing activities	\$ 244,271	\$ 1,111	
Cash and cash equivalents - beginning of period 218,781 90,32	Net increase (decrease) in cash and cash equivalents	231,899	(63)	
Cash and cash equivalents - end of period \$ 450,680 \$ 90,25	Cash and cash equivalents – beginning of period	218,781	90,315	
	Cash and cash equivalents – end of period	\$ 450,680	\$ 90,252	

Supplemental information of non-cash investing and financing information:		
Right-of-use assets obtained in exchange for operating lease liabilities	\$ 81 \$	3,185
Property and equipment acquisitions through finance leases	\$ 203 \$	827
Deferred offering costs included in accounts payable and accrued expenses	\$ 362 \$	
Purchase of property and equipment and capitalized software included in accounts payable	\$ 351 \$	791
Cash payments for:		
Interest	\$ 156 \$	306

Non-GAAP financial measures

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss before interest expense (income), net, provision for (benefit from) income taxes, depreciation and amortization, and before stock-based compensation expense, change in fair value of contingent consideration liabilities and other (income) expense, net.

We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Annual Report on Form 10-K because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

- Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation;
 (3) tax payments that may represent a reduction in cash available to us; or (4) Interest expense (income), net; and
- Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated:

Phreesia, Inc. Adjusted EBITDA (Unaudited)

	Three Months ended April 30,				
(in thousands)		2021 2020			
Net loss	\$	(10,974)	\$	(6,112)	
Interest expense (income), net		238		320	
Provision for income taxes		149		111	
Depreciation and amortization		4,948		3,621	
Stock-based compensation expense		5,774		2,872	
Other (income) expense, net		(66)		715	
Adjusted EBITDA	\$	69	\$	1,527	

Phreesia, Inc. Reconciliation of GAAP and Adjusted Operating Expenses (Unaudited)

		Three Months ended April 30,				
(in thousands)		2021		2020		
GAAP operating expenses						
General and administrative		12,671		8,720		
Sales and marketing		15,012		9,434		
Research and development		8,054		5,005		
Cost of revenue		8,534		4,734		
	\$	44,271	\$	27,893		
Stock compensation included in GAAP operating expenses						
General and administrative	\$	2,918	\$	1,606		
Sales and marketing		1,646		728		
Research and development		844		452		
Cost of revenue		366		86		
	\$	5,774	\$	2,872		
Adjusted operating expenses						
General and administrative	\$	9,753	\$	7,114		
Sales and marketing		13,366		8,706		
Research and development		7,210		4,553		
Cost of revenue		8,168		4,648		
	\$	38,497	\$	25,021		

Phreesia, Inc. Key Metrics (Unaudited)

	Three months ended April 30,			
	 2021	2020		
Key Metrics:				
Provider clients (average over period)	1,902		1,632	
Average revenue per provider client	\$ 20,222	\$	16,735	

Provider clients. We define provider clients as the average number of healthcare provider organizations that generate revenue each month during the applicable period. In cases where we act as a subcontractor •

providing white-label services to our partner's clients, we treat the contractual relationship as a single provider client. We believe growth in the number of provider clients is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our Platform to healthcare provider organizations that are not yet clients. While growth in the number of provider clients is an important indicator of expected revenue growth, it also informs our management of the areas of our business that will require further investment to support expected future provider client growth. For example, as the number of provider clients we may need to add to our customer support team and invest to maintain effectiveness and performance of our Platform and software for our provider clients and their patients.

Average revenue per provider client. We define average revenue per provider client as the total subscription and related services and payment processing revenue generated
from provider clients in a given period divided by the average number of provider clients that generate revenue each month during that same period. We are focused on
continually delivering value to our provider clients and believe that our ability to increase average revenue per provider client is an indicator of the long-term value of the
Phreesia platform.

Additional Information

(Unaudited)	
-------------	--

	_	Three mon Apri	l
		2021	2020
Patient payment volume (in millions)	\$	701	\$ 454
Payment facilitator volume percentage		78 %	84 %

- Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our provider clients' businesses and the continuing shift of
 healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our provider clients and their patients utilizing our payment
 platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which Phreesia
 acts as a gateway to other payment processors.
- Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payment volume that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing revenue.

Available Information

Phreesia intends to use its Company website (including its Investor Relations website) as well as its Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Forward Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In "ome cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend, "ipan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements are reasonable.

and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, statements about our future financial performance, including our revenue, cash flows, costs of revenue and operating expenses; our anticipated growth; our predictions about our industry; the impact of the COVID-19 pandemic on our business and our ability to attract, retain and cross-sell to healthcare provider clients. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission ("SEC"), including in our Quarterly Report on Form 10-Q for the fiscal year ended April 30, 2021 that will be filed with the SEC following this earnings release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures.

ABOUT PHREESIA

Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.

Investors:

Balaji Gandhi Phreesia, Inc.

investors@phreesia.com (929) 506-4950

Media:

Annie Harris Phreesia, Inc.

aharris@phreesia.com

(929) 526-2611